CDISC Teams Up with Microsoft to Develop Open-Source Software for the Clinical Research Community

CDISC is teaming up with Microsoft to develop the CDISC Open Rules Engine (CORE), open-source software that executes machine-readable CDISC Conformance Rules. The global clinical research community will be able to leverage the CORE software to test study data for conformance to CDISC standards as well as regulatory and sponsor-specific conformance rule sets.

CDISC Conformance Rules as well as regulatory agency rules provide a critical quality check in ensuring study data conform to CDISC standards. An emerging industry best practice is to use Conformance Rules on an ongoing basis, throughout the study, to keep the data as close to submission ready as possible and to ensure quality in all data exchange scenarios. The free and open, Microsoft Azure-based CORE will execute Conformance Rules retrieved from the CDISC Library against standardized clinical research data and produce a report detailing the findings, which will allow researchers to receive, process, and review study data more efficiently and effectively.

"We are excited to work with Microsoft on another important initiative that extends our current work in support of standards-based process automation," said Sam Hume, CDISC VP, Data Science. "We look forward to building a community around CORE that will collaborate to create new innovative features and solutions."

"Microsoft is pleased to expand our work with CDISC to build the next generation CDISC Open Source Rules Engine to support Pharma Industry's digital transformation goals and ultimately accelerate time to market for life saving therapies." - Patty Obermaier, VP of Health and Life Sciences, Microsoft US.

To support and grow a community of open-source software developers, CDISC has initiated the CDISC Open Source Alliance (COSA). Several CDISC member organizations as well as individual developers have already committed to participate in COSA. Microsoft will provide ongoing guidance. Once released, CORE will become a COSA project supported by a global team of open-source developers and CDISC. A key component of COSA is community development.

CDISC collaborated with Microsoft on the Azure-based CDISC Library and CDISC 360, two projects that support standards-based process automation throughout the clinical research data lifecycle.

About CDISC

CDISC creates clarity in clinical research by convening a global community to develop and advance data standards of the highest quality. Required by the United States Food and Drug Administration (FDA) and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), recommended by the China National Medical Products Administration (NMPA) and adopted by the world's leading research organizations, CDISC standards enable the accessibility, interoperability, and reusability of data. With the help of CDISC standards, the entire research community can maximize the value of data for more efficient and meaningful research that has invaluable impact on global health. CDISC is a 501(c)(3) global nonprofit charitable organization with administrative offices in Austin, Texas, with hundreds of employees, volunteers, and member organizations around the world.

Most Popular Now

Almost All Leading AI Chatbots Show Sign…

Almost all leading large language models or "chatbots" show signs of mild cognitive impairment in tests widely used to spot early signs of dementia, finds a study in the Christmas...

New Study Reveals Why Organisations are …

The slow adoption of blockchain technology is partly driven by overhyped promises that often obscure the complex technological, organisational, and environmental challenges, according to research from the University of Surrey...

Emotional Cognition Analysis Enables Nea…

A joint research team from the University of Canberra and Kuwait College of Science and Technology has achieved groundbreaking detection of Parkinson's disease with near-perfect accuracy, simply by analyzing brain...

New Recommendations to Increase Transpar…

Patients will be better able to benefit from innovations in medical artificial intelligence (AI) if a new set of internationally-agreed recommendations are followed. A new set of recommendations published in The...

Digital Health Unveils Draft Programme f…

18 - 19 March 2025, Birmingham, UK. Digital Health has unveiled the draft programme for its Rewired 2025 event which will take place at the NEC in Birmingham in March next...

AI System Helps Doctors Identify Patient…

A new study from Vanderbilt University Medical Center shows that clinical alerts driven by artificial intelligence (AI) can help doctors identify patients at risk for suicide, potentially improving prevention efforts...

Smartphone App can Help Reduce Opioid Us…

Patients with opioid use disorder can reduce their days of opioid use and stay in treatment longer when using a smartphone app as supportive therapy in combination with medication, a...

AI's New Move: Transforming Skin Ca…

Pioneering research has unveiled a powerful new tool in the fight against skin cancer, combining cutting-edge artificial intelligence (AI) with deep learning to enhance the precision of skin lesion classification...

Leveraging AI to Assist Clinicians with …

Physical examinations are important diagnostic tools that can reveal critical insights into a patient's health, but complex conditions may be overlooked if a clinician lacks specialized training in that area...

AI can Improve Ovarian Cancer Diagnoses

A new international study led by researchers at Karolinska Institutet in Sweden shows that AI-based models can outperform human experts at identifying ovarian cancer in ultrasound images. The study is...

Major EU Project to Investigate Societal…

A new €3 million EU research project led by University College Dublin (UCD) Centre for Digital Policy will explore the benefits and risks of Artificial Intelligence (AI) from a societal...

Predicting the Progression of Autoimmune…

Autoimmune diseases, where the immune system mistakenly attacks the body's own healthy cells and tissues, often have a preclinical stage before diagnosis that’s characterized by mild symptoms or certain antibodies...